Identification of cellular and genetic drivers of breast cancer heterogeneity in genetically engineered mouse tumour models by Melchor, Lorenzo et al.
1 
 
Identification of Cellular and Genetic Drivers of Breast Cancer 
Heterogeneity in Genetically Engineered Mouse Tumour Models 
 
Lorenzo Melchor*1,2, Gemma Molyneux*1,3, Alan Mackay1, Fiona-Ann Magnay1, 
María Atienza4, Howard Kendrick1,5, Daniel Nava-Rodrigues1, María Ángeles López-
García4, Fernanda Milanezi1,6, Kirsty Greenow5, David Robertson1, José Palacios7, 
Jorge S. Reis-Filho8 and Matthew J. Smalley1,5,9. 
 
*These authors contributed equally to this study. 
 
1Division of Breast Cancer Research, Breakthrough Breast Cancer Research Centre, 
The Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, United 
Kingdom 
 
2Current address: Centre for Myeloma Research, Division of Molecular Pathology, 
The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK 
 
3Current address: Centre for Molecular and Cellular Biology of Inflammation, Division 
of Immunology Infection & Inflammatory Diseases, King's College London, 1st Floor 
New Hunt's House, Great Maze Pond, London SE1 1UL, UK 
 
4Department of Pathology, Instituto de Biomedicina de Sevilla, CSIC-Universidad de 
Sevilla, Hospital Universitario del Rocío, Seville, Spain 
 
 
2 
 
5Current address: European Cancer Stem Cell Research Institute, Cardiff School of 
Biosciences, Cardiff University, Hadyn Ellis Building, Maindy Road, CF24 4HQ, 
United Kingdom 
 
6Current address: Salomao & Zoppi Diagnósticos, 876 Divino Salvador Avenue, Sao 
Paulo, SP, Brazil 
 
7Department of Pathology, Hospital Universitario Ramón y Cajal, Instituto Ramón y 
Cajal de Investigaciones Sanitarias, Madrid, Spain 
 
8Department of Pathology, Memorial Sloan-Kettering Cancer Center, 1275 York 
Avenue, New York, NY, USA, 10065 
 
9Corresponding author. Telephone: +44(0)29 208 75862 FAX: +44(0)29 208 74116 
E-mail: SmalleyMJ@Cardiff.ac.uk 
 
Running title: Breast cancer heterogeneity in mouse tumour models 
 
Conflict of interest statement: The authors declare they have no conflicts of 
interest in the publication of this manuscript. 
 
Word count (beginning of introduction to end of discussion): 3999 
 
 
  
3 
 
Abstract 
The heterogeneous nature of mammary tumours may arise from different initiating 
genetic lesions occurring in distinct cells of origin. Here, we generated mice in which 
Brca2, Pten and p53 were depleted in either basal mammary epithelial cells or 
luminal oestrogen receptor (ER) negative cells. Basal cell-origin tumors displayed 
similar histological phenotypes regardless of the depleted gene. In contrast, luminal 
ER negative cells gave rise to diverse phenotypes, depending on the initiating 
lesions, including both ER negative and, strikingly, ER positive Invasive Ductal 
Carcinomas. Molecular profiling demonstrated that luminal ER negative cell-origin 
tumours resembled a range of the molecular subtypes of human breast cancer, 
including basal-like, luminal B and ‘normal-like’. Furthermore, a subset of these 
tumours resembled the ‘claudin-low’ tumour subtype. These findings demonstrate 
that not only do mammary tumour phenotypes depend on the interactions between 
cell-of-origin and driver genetic aberrations, but also that multiple mammary tumour 
subtypes, including both ER positive and negative disease, can originate from a 
single epithelial cell type. This is a fundamental advance in our understanding of 
tumour etiology. 
 
Keywords: Brca2, Pten, p53, tumour heterogeneity, breast cancer molecular 
subtypes, basal-like. 
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Introduction 
Breast cancer is a heterogeneous disease encompassing different histological and 
molecular subtypes with distinct clinical behaviours[1-4]. The biological basis of this 
heterogeneity remains poorly understood; improving this understanding is key to 
better patient stratification. Although distinct molecular events occurring in different 
target cells may explain the variety of breast cancer phenotypes[5, 6], there is not 
necessarily a direct correlation between tumour phenotype and its cell-of-origin. For 
instance, breast cancers of ‘basal-like’ subtype were proposed to arise from basal 
stem cells[7-10], but current models suggest that a substantial proportion, if not all, 
of these tumours derive from luminal-progenitor cells[11-13]. Disentangling the 
complex relationship between tumour-initiating genetic events, target cells and 
tumour phenotypes is ideally suited to studies using genetically engineered mouse 
models. 
  
We previously demonstrated that when Brca1 and p53 loss were targeted to either 
basal or luminal ER negative mammary (lumERneg) cells in mouse models, the 
balance of tumour phenotypes depended on the cell-of-origin. Though all tumours 
were molecularly classified as ‘basal-like’, histologically the basal-cell origin tumours 
were mostly adenomyoepitheliomas (AMEs) while the lumERneg-cell origin tumours 
were high grade Invasive Ductal Carcinomas of No Special Type (IDC-NSTs)[13]. It 
remains to be defined, however, whether the cell-of-origin is the prime determinant of 
tumour subtype or if initiating genetic hits also play a role in shaping phenotype, in 
addition to simply stimulating tumourigenesis. 
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To address this question, we generated conditional mouse models where Brca2, p53 
and/or Pten were deleted in distinct cell populations of the mouse mammary gland. 
To fully describe the tumours these animals developed, detailed histopathological, 
immunohistochemical and gene expression analyses were performed. We 
demonstrate that the relative contributions of cell-of-origin and molecular lesion to 
determining mammary tumour heterogeneity are context dependent. The final 
tumour phenotype is the result of both interactions between the cell-of-origin and 
genetic aberrations, and epistatic interactions between genetic aberrations within a 
cancer. 
 
Materials and Methods 
Tumour cohorts 
The following genotypes were established and maintained until tumours developed: 
K14Cre:Brca2f/f:p53f/f, BlgCre:Brca2f/f:p53f/f virgin and parous, Pten+/-, K14Cre:Ptenf/f; 
BlgCre:Ptenf/f virgin and parous, BlgCre:Ptenf/f:p53f/+, BlgCre:Ptenf/f:p53f/f. Parous 
mice went through 2-3 pregnancy cycles. Tumours were excised from humanely 
killed mice and half was fixed in 4% phosphate-buffered formalin (BIOS Europe Ltd, 
Skelmesdale, UK) overnight for paraffin-embedding. The remainder was snap-frozen 
on dry ice for nucleic acid isolation. 
 
Histology and immunohistochemistry 
Haematoxilin and eosin (H&E) staining was performed using standard methods. 
Immunohistochemisty for ER, p63, K14 and K18 and double p63/ER 
immunofluorescence were carried out as described[13, 14]. Immunohistochemistry 
for PRA (hPRa7; ThermoScientific, UK) and PRB (alphaPR6; Abcam, Cambridge, 
6 
 
UK) were performed using the ER protocol. Immunohistochemistry for human 
CLDN3 (Z23.JM, Invitrogen-Life, Paisley, UK), CLDN4 (3E2C1, Invitrogen-Life), 
CDH1 (Zymed, CA, USA) and PTEN (6H2.1; Dako, Denmark) were performed as 
described[15, 16]. 
 
Gene expression microarray analysis 
Samples which underwent gene expression analysis were morphologically checked 
to be representative. Microarray hybridisation was performed by UCL Genomics 
(UCL, London, UK) using the Affymetrix GeneChip Mouse Genome 430 2.0 Array 
(Affymetrix, Santa Clara, CA, USA). Data were read using the Affymetrix package in 
R (v.2.11.0) and annotated using Bioconductor 2.8. Arrays were normalised with the 
RMA method in Expression Console 1.1 and annotated with corresponding human 
orthologue annotation based upon the Mouse Genome Informatics database 
(http://www.informatics.jax.org/). Sub-group assignment was performed based upon 
nearest-centroid Spearman rank correlation over 0.1 as described[13, 17] using 
published centroid data[18]. Meta-analysis of the mouse tumour signatures in human 
breast cancers is fully described in Supplementary Online Material. MIAME 
compliant data are available (ArrayExpress, E-MEXP-3663). 
 
Results 
To determine how different cells-of-origin interact with different initiating genetic 
lesions to drive tumour heterogeneity, we generated mouse cohorts carrying 
conditional alleles of Brca2, p53 and Pten together with either K14Cre or BlgCre, 
which preferentially target tumour formation to basal- or lumERneg-cells, 
respectively[13]. Cohorts of virgin/parous BlgCre animals were established. For 
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additional information about mouse cohorts, cells of origin of the tumours and full 
tumour details see Supplementary Information and Tables S2-S3. 
 
Cell-of-origin drives tumour phenotype in Brca2-deleted mammary tumours 
All three cohorts of mice carrying conditional Brca2 and p53 alleles 
(K14Cre:Brca2f/f:p53f/f, virgin BlgCre:Brca2f/f:p53f/f and parous BlgCre:Brca2f/f:p53f/f) 
developed mammary tumours. Median latency was significantly shorter (p<0.0001, 
log-rank test) in K14Cre:Brca2f/f:p53f/f (197 days; range 47-243 days) animals 
compared with either virgin (242d; 185-334d) or parous (275.5d; 133-445d) 
BlgCre:Brca2f/f:p53f/f mice (Figure 1A). Significant reduction in conditional p53 and 
Brca2 expression was shown in all tumours relative to control spleens, concordant 
with deletion of floxed exons (Figure S1). Droplet digital PCR (ddPCR) demonstrated 
that tumours consistently had fewer copies of floxed Brca2 and p53 exons compared 
to unfloxed exons (Figure S2). However, the presence of infiltrating immune cells 
(Table S2), and likely contamination of tumour samples by other wild-type host cells, 
meant that tumours rarely showed a floxed allele number which approached zero. 
 
BlgCre:Brca2f/f:p53f/f tumours were classified mainly as either IDC-NSTs (13/29, 
44.8%; Figure 1B; Figure 2A-F) or Metaplastic Spindle Cell Tumours (MSCTs; 14/29, 
48,3%; Figure 2G-L). Tumours were high grade with pushing/mixed borders, a high 
nuclear pleomorphism, little or no tubule formation and a high mitotic index (MI; 
Figure 1C, Figure 2B). Most tumours (25/29; 86%) were positive for keratin 14 and 
keratin 18 (K14 and K18, expressed in basal- or luminal-cells respectively in the 
normal mammary epithelium) and were weakly positive for p63. The majority (24/29) 
were also ER-negative (Figure 1D-F; Figure 2C-F,2I-L). In contrast, histological 
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analysis of K14Cre:Brca2f/f:p53f/f tumours demonstrated that most tumours (7/11; 
64%) were malignant-AMEs (Figure 1B, Figure 2M-R). All tumours were of high 
histological grade, with significantly higher MI (Figure 1C; p<0.01, K14Cre-vs-
parous-BlgCre; p<0.001, K14Cre-vs-virgin-BlgCre, unpaired two-tailed t-test), and 
had multifocal necrosis. Tumours were K14/K18-positive with a distinguishable 
distribution of K14- and K18-positive cells in abluminal- and luminal-cell layers, 
respectively, consistent with the AME diagnosis (Figure 1D,E; Figure 20,P). 
Compared with BlgCre tumours, K14Cre tumours had stronger p63 staining in 
significantly more (Figure 1F, p<0.001, unpaired two-tailed t-test) cells in each 
tumour (range 5-90%, predominantly in the abluminal-cell layer; Figure 2Q). Of 
K14Cre tumours in which ER staining was determined, half (4/8; 50%) were ER-
negative (Figure 2R), three contained ≤5% ER-positive cells but one had around 
40% ER-positive cells. In both BlgCre and K14Cre Brca2 tumours, PR-staining was 
concordant with ER-staining, although typically fewer cells were PRA-positive than 
ER-positive, and fewer still were PRB-positive than PRA-positive. Thus, in some 
cases, weakly ER-positive tumours were PR-negative (Table S2). Therefore, 
targeted deletion of Brca2 and p53 in basal- or lumERneg-cells resulted in tumours 
with different latencies and histopathological features. 
 
The tumour-initiating lesion determines the phenotype of luminal ERneg-origin 
tumours 
Next, we examined K14Cre:Ptenf/f, BlgCre:Ptenf/f and BlgCre:Ptenf/f:p53f/+&f/f mice as 
well as germ-line Pten heterozygote mice (Pten+/-). Due to a strong skin phenotype, 
only fourteen K14cre:Ptenf/f mice could age older than four months old. From these, 
only 5 mammary tumours were obtained (from four mice). Mammary tumour 
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latencies in K14Cre:Ptenf/f (141-386d), virgin BlgCre:Ptenf/f (340d; 128-711d), parous 
BlgCre:Ptenf/f (357d; 245-771d), and Pten+/- mice (368d; 100-434d), were not 
significantly different (Figure 1G). However, BlgCre:Ptenf/f:p53f/+&f/f mice developed 
tumours (312d; 139-361d) significantly faster than parous BlgCre:Ptenf/f mice 
(p<0.05, log rank test) and also faster, though not significantly potentially due to the 
small sample size, than virgin BlgCre:Ptenf/f mice (p=0.078, log rank test; Figure 1G).  
 
All tumours had lower expression for Pten floxed exon 4 compared with exon 6 
(Figure S3A,B), confirming recombination of the conditional allele during 
tumourigenesis. Expression of p53 exon 4 was higher in Ptenf/f tumours, similar or 
lower in Ptenf/f:p53f/+ tumours, and always reduced in Ptenf/f:p53f/f tumours relative to 
control spleen (Figure S3C). This is consistent with Pten loss causing p53 induction 
in p53+/+ mice and a dose-dependent reduction in this response following loss of one 
or two p53 alleles[19]. Again, ddPCR demonstrated that tumours from 
BlgCre:Ptenf/f:p53f/+&f/f mice had fewer copies of floxed p53 exons compared to 
unfloxed exons (Figure S2). The same caveats regarding infiltrating immune cells 
apply (Table S2). For technical reasons, the ddPCR assay could not be performed 
on the floxed Pten allele. 
 
Pten depletion generated both malignant and benign neoplasms regardless of the 
origin cell type (Tables S2, S3). Benign tumours were classified as sclerosing 
adenosis and benign-AMEs (Figure 3A-F), with 5/15 (33%) displaying papillary 
architecture (Figure S4A-F). All showed strong K14, K18, p63, and ER staining 
(Figure 3C-F, Figure S4C-J). 
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In contrast to IDC-NSTs/MSCTs developing from lumERneg-cells in Brca2:p53 mice, 
malignant lumERneg-origin Ptenf/f tumours were AMEs (4/10; 40%) or metaplastic 
Adenosquamous Carcinomas (ASQCs; 4/10; 40%) with two additional tumours 
showing both elements (Figure 1H, Figure 3G-R, Table S2). A subset displayed 
papillary architecture (Figure S4L-Q). Tumours had pushing/mixed borders, 
central/multifocal necrosis and low/intermediate histological grades with intermediate 
nuclear pleomorphism, tubule formation and MI (Figure 1I). Metaplastic squamous 
cells were found in 8/10 (80%) tumours (5-75% cells; Figure 3N). All tumours were 
positive for K14, K18, and p63 (Figure 1J-L; Figure 3I-K, 3O-Q). Remarkably, strong 
ER expression was seen in 7/8 (87.5%) analysed malignant tumours (15-40% cells; 
Figure 3L, 3R; Figure S5). PRA expression was observed in 8/9 analysed tumours 
(1-30% cells; Figure S5). Notably, both malignant Pten+/- and K14Cre:Pten tumours 
had similar phenotypes to lumERneg-cell origin tumours (Table S2). 
 
Addition of p53 conditional alleles into the BlgCre:Pten cohort increased the ratio of 
malignant to benign tumours, with 20/21 (95%) tumours being malignant (Table S2). 
It also shifted the spectrum of histopathological phenotypes closer to that seen with 
BlgCre:Brca2f/f:p53f/f cohorts (Figure 1B, 1H), as half of all BlgCre:Ptenf/f:p53f/+&f/f 
tumours were classed as either IDC-NSTs (5/20; Figure 4A-F) or MSCTs (6/20, 
Figure 4G-L). The remainder were diagnosed as malignant-AMEs (2/20, 10%; Figure 
4M-R), ASQCs (4/20, 20%) or mixed tumours (3/20, 15%). 
 
As opposed to the low/intermediate histological grades of Pten tumours, 
BlgCre:Ptenf/f:p53f/+&f/f carcinomas showed high histological grade, with high nuclear 
pleomorphism, lack of tubule formation and high MI (Figure 1I). Tumours had mixed 
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borders, with central/multifocal necrosis. Spindle (5-100%) and squamous (1-50%) 
metaplastic cells were seen in all tumours. All were K14/K18-positive (Figure 1J,K), 
but staining tended to be at low levels in IDC-NSTs (5-25%; Figure 4C,D), at very 
low levels in MSCTs (1-10%; Figure 4I,J), and at the highest levels in AMEs (40-
60%; Figure 4O,P). p63 staining was positive in 18/20 (90%) tumours (1-80% cells) 
(Figure 1L; Figure 4E,K,Q). Again, IDC-NSTs and MSCTs had few p63-positive cells 
and these were scattered through the tumour whereas AMEs had high levels of p63 
staining organised into distinct abluminal epithelial layers and ‘nests’ of p63-positive 
neoplastic cells (Figure 4E,K,Q). ER staining was intense and frequent in tumour 
cells in 17/20 (85%) carcinomas (1-30% cells; Figure S5) including IDC-NSTs 
(Figure 4F,R) but was either absent or expressed at low levels in MSCTs. Like the 
Brca2 cohorts, PR staining was concordant with ER staining, with fewer cells PRA-
positive than ER-positive, and fewer still PRB-positive than PRA-positive (Figure S5 
and Table S2). Double immunofluorescence staining of benign and malignant 
BlgCre:Ptenf/f AMEs, as well as malignant BlgCre:Ptenf/f:p53f/+&f/f AMEs, 
demonstrated that in benign tumours p63-positive and ER-positive cell populations 
were mutually exclusive but in malignant tumours most of p63-positive cells were 
also ER-positive (Figure S6). This double positivity for ER/p63 suggests an aberrant 
differentiation in these tumour cells. 
 
Therefore, BlgCre:Brca2f/f:p53f/f and BlgCre:Ptenf/f mouse models showed distinct 
differences in tumour latency and phenotype despite the initiating genetic lesions 
being targeted to the same cell population. This demonstrated that in these cases 
the cell-of-origin was not the sole determinant of tumour phenotype. Rather, the 
initiating genetic hits underpinned tumour behaviour and phenotype. Targeted 
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deletion of both Pten and p53 to lumERneg-cells accelerated tumour formation and, 
notably, resulted in a range of phenotypes that once again included IDC-NSTs and 
MSCTs. BlgCre:Ptenf/f:p53f/+&f/f IDC-NSTs, however, were strongly ER-positive, 
unlike IDC-NSTs from other cohorts (BlgCre:Brca2f/f:p53f/f and BlgCre:Brca1f/f:p53+/-) 
[13, 20]. 
 
Luminal ERneg-origin tumours display diverse molecular profiles determined by 
the initiating genetic lesion 
We performed whole transcriptome analysis of a subset of tumours from each 
genotype (including a previous collection of K14Cre:Brca1f/f:p53+/- and 
BlgCre:Brca1f/f:p53+/- tumours)[13] using the Affymetrix MouseChip Genome 
platform. Unsupervised hierarchical clustering showed the tumours broadly clustered 
into three molecular groups (Figure 5). One included the Brca2:p53 tumours and the 
Pten:p53 tumours; the second group consisted of most of Pten-only tumours; the 
third group included Brca1:p53 tumours and some Pten tumours. Pairwise SAM 
comparisons between groups delivered a list of significantly-associated genes, which 
were interrogated for GO terms and KEGG pathway analysis (Table S4). The 
Brca2:p53/Pten:p53 group (group 1) and the Brca1:p53 group (group 3) genes were 
highly enriched for GO Bioprocess annotations associated with transcription, 
metabolism, biosynthesis and regulation of cell death. In contrast, the group 2 (Pten) 
genes were enriched for development, homeostasis, signalling and regulation of cell 
death Bioprocesses and expressed genes involved in ‘response to hormone 
stimulus’ and ‘steroid metabolic process’. Pathway analysis showed a great similarity 
between all tumour groups (Table S4), although with some differences. For instance, 
group 1 was enriched for genes associated with adhesion, junctional complexes and 
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JAK-STAT signalling pathways, group 2 with genes associated with calcium 
signalling and vascular smooth muscle pathways, and group 3 with genes 
associated with the cell cycle and DNA replication pathways. Interestingly, genes for 
cysteine and methionine metabolism pathways were enriched in groups 1 and 3 
while genes for glycine, serine, threonine and tyrosine metabolism pathways were 
enriched in group 2, suggesting fundamental differences in the metabolism of these 
tumour groups. 
 
Importantly, these molecular clusters were determined by the initiating genetic lesion 
(Figure 5C), with expression profiles being consistent across tumours carrying the 
same initiating lesion. Tumours with different lesions were not randomly interspersed 
nor did tumours cluster by Cre promoter. Thus, the tumour molecular profile was 
governed by its initiating genetic lesion, not by the cell to which those lesions were 
targeted. 
 
Luminal ERneg-cells generate Basal-like, ‘Normal breast-like’, Luminal A and 
Luminal B tumours 
We next asked which human breast cancer molecular subtypes the mouse tumours 
of this analysis most closely resembled, using a single sample predictor gene set 
(SSP)[18] (Table 1, Figure 5E, Table S5). Consistent with their lack of ER 
expression, 9/13 (70%) Brca2:p53 mouse tumours classed as basal-like using the 
PAM50 gene set, irrespective of whether they were from the K14Cre or BlgCre 
cohorts. Of the Pten tumours, 17/21 (81%) tumours were categorised as ‘normal 
breast-like’, three tumours classed as luminal A, and one as basal-like. Conversely, 
Pten:p53 tumours were classified as luminal B (4/10), ‘normal breast-like’ (3/10), 
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luminal A (2/10) and one could not be assigned to any subtype. Differences in the 
proportions of the predominant subtypes within each genotype were highly 
significant (p<0.0001, test) in pairwise genotype comparisons (Table 1). 
 
PAM50 analysis is sensitive to sample cohort normalisation issues[17]. We therefore 
interrogated different human breast tumour transcriptome datasets[1, 3, 18, 21-23], 
including three enriched for BRCA1/2 mutation carriers[24-26], using mouse tumour 
transcriptome signatures. We built three mouse molecular signatures based upon 
the top probes up- and down-regulated within each mouse group (Pten only; 
Brca1:p53 only; combined Brca2:p53/Pten;p53) identified by SAM pairwise 
comparisons. Signatures were applied to each sample from each dataset. 
Correlation heatmaps for the mouse transcriptome signature in the human datasets 
(Figure 5F, Figure S8) confirmed, first, that the Brca1:p53 mouse signature was 
associated with the human basal-like subtype and with human BRCA1 breast 
cancers; second, that luminal A, normal-breast-like and non-BRCA1/2 cancers were 
enriched in breast cancer samples with a gene signature similar to the Pten mouse 
tumours; and third, that the Brca2:p53/Pten:p53 signature was observed across the 
range of human breast cancer molecular subtypes. Notably, when testing human 
breast cancer datasets that included the claudin-low subtype, a particular enrichment 
for the Brca2:p53/Pten:p53 signature was obtained in this group. The 
Brca2:p53/Pten:p53 signature was not enriched in human BRCA2 tumours; indeed, 
in one study [25] the association was with BRCA1 tumours. 
 
These results showed that tumours deriving from the same cell-of-origin, lumERneg-
cells, not only had very different molecular features depending on the initiating 
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genetic lesions, but also spanned a broad range of human-equivalent molecular 
signatures. Hence, the ‘intrinsic subtype’ classification of a tumour does not 
necessarily reflect its cell-of-origin. 
 
Luminal ERneg-cells generate ‘claudin-low’ tumours 
The claudin-low subtype is not distinguished by the PAM50 gene set. This subtype is 
characterised by upregulation of mesenchymal-associated genes and 
downregulation of genes related to epithelial cell–cell junctions, particularly claudins 
CLDN3, 4 and 7, and CDH1[22]. As a ‘mesenchymal-like’ appearance was typical of 
the MSCTs from our tumour cohorts, and enrichment for the Brca2:p53/Pten:p53 
signature, both tumour genotypes with high numbers of MSCTs, was observed in the 
claudin-low subtype in breast cancer datasets which included that group, we 
analysed expression of Cldn3, 4 and 7 and Cdh1 across the tumour panel 
categorised by histological phenotype. The results confirmed that MSCTs had 
significantly lower expression levels of these four genes compared to other tumour 
types (Figure 6) and indeed of the whole geneset reported as downregulated in the 
claudin-low phenotype[22] (Figure S9). This demonstrates that the transcriptomic 
signature of MSCTs recapitulates that of claudin-low tumours, suggesting that this 
tumour type can also originate from lumERneg-cells. 
 
Human metaplastic tumours have variable PTEN expression but express low-
claudin levels 
Using a pilot cohort of human breast cancers, including some very rare human 
AMEs, we examined if there was an association between PTEN expression and the 
human histological phenotypes equivalent to those in our mouse cohorts. We found 
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that staining of metaplastic tumours and IDC-NSTs was variable but the few human 
AMEs we examined were very strongly PTEN-positive (Table S6, Figure S10). 
 
We also examined the same tumour group for expression of CLDN3, CLDN4 and 
CDH1. Unlike PTEN staining, these results were concordant with the mouse data, as 
human IDC-NSTs expressed high protein levels but there was absence of 
expression in non-epithelial areas of spindle-cells carcinomas and metaplastic 
carcinomas with mesenchymal differentiation (Table S6, Figure S10). 
 
Discussion 
Inter-tumour heterogeneity must arise from different (epi)genetic lesions occurring in 
different cells of origin. Here, we have applied histopathological and molecular 
pathology approaches to analyse tumours arising in genetically engineered mouse 
models from different initiating lesions in distinct cells of origin. We show that in our 
model system targeting tumour-initiating lesions to basal-cells results primarily in 
adenomyoepitheliomas, whereas targeting lumERneg-cells results in tumours with a 
range of histopathological features including metaplastic tumours and invasive ductal 
carcinomas[4]. Importantly, we have generated both ER-positive luminal-like and 
ER-negative basal-like tumours from this target population. We have also shown that 
the initial genetic lesion is the prime determinant of the molecular profile of the 
subsequent tumours arising from these cells. This suggests that rather than being a 
truly stochastic process, the etiology of tumour formation is largely deterministic and 
depends on the earliest events in carcinogenesis (i.e. the founder genetic/ epigenetic 
events).  
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Germ-line mutations in human BRCA2 predispose to breast and ovarian cancers[27]. 
Although 66-93% of BRCA2-associated human cancers are ER-positive in >10% 
tumour cells[28, 29], only 3/15 (20%) of the Brca2 IDC-NSTs described here were 
ER-positive (1-10% tumour cells). As the same cells of origin could generate ER-
positive IDC-NSTs in the Pten:p53 model, this is unlikely explained by a lack of 
potential to differentiate along this lineage. Moreover, most of the Brca2 mouse 
tumours had a molecular profile similar to human basal-like breast cancers (Table 1, 
Figure 5F) and did not resemble a typical human BRCA2 tumour profile (Figure S8). 
It should be noted, however, that a subset (13-19%) of human BRCA2-mutated 
breast cancers have a basal-like molecular profile and are also ER-negative [30], 
which would be consistent with the similarity of the Brca2:p53/Pten:p53 signature to 
human BRCA1 tumours in data from one study[25]. It is possible that 
BlgCre:Brca2:p53 tumours model the basal-like subset of human BRCA2 breast 
cancers. 
 
Loss of PTEN expression is recurrent in human breast cancers, in both basal and 
luminal subtypes[3]. In our study, targeting conditional depletion of Pten alone to 
mouse lumERneg-cells resulted in a different effect to Brca1/2:p53 loss, leading to the 
development of benign- and malignant-AMEs, and ASQCs. Notably, AMEs were 
highly differentiated and ER-positive. In contrast, analysis of a pilot cohort of human 
breast cancers, including very rare human AMEs, found strong PTEN expression in 
these tumours. Larger numbers are required to confirm these findings but they 
suggest that human AMEs are not associated with somatic PTEN loss, unlike in the 
mouse. Notably, however, breast tumours from germ-line PTEN-loss-syndrome 
families are enriched for molecular apocrine differentiation, which is characterised by 
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elevated levels of androgen signalling[31], and our mouse Pten tumour cohort also 
expressed high levels of the Androgen Receptor (Table S4). The mouse tumour 
phenotypes were altered when conditional Pten:p53 alleles were combined, resulting 
in the development of MSCTs and ER-positive IDC-NSTs. In these tumours, the 
molecular changes observed (loss of claudins in MSCTs) were reflected in the 
equivalent human tumours. 
 
Our findings show that a broad spectrum of tumour phenotypes can emerge from the 
lumERneg-cell population, they suggest that p53 loss-of-function is a prime driver of 
histopathological phenotype and they demonstrate that, in contrast, cell-of-origin is 
not a strict driver of tumour phenotype. Our results are consistent with the notion that 
mammary tumour heterogeneity is a result of context-dependent interactions 
between cell-of-origin and early genetic hits. In the K14Cre basal-origin tumours we 
describe, the AME phenotype is the default tumour type irrespective of the driving 
genetic lesion. Conversely, lumERneg-cells are able to generate a broad spectrum of 
tumour histological and molecular phenotypes, including highly aggressive ER/PR-
negative and ER/PR-positive neoplasms. Since tumours had long latency periods, 
and additional genetic mutations must have arisen in all genetic backgrounds to 
permit tumour formation, the stability of histological phenotypes within each genetic 
background was notable. Either any additional genetic hits were stochastic and had 
little effect on overall tumour phenotype or each cell-of-origin/genetic background 
combination developed a set of stereotypical lesions that contributed to the tumour 
phenotype. Future massively-parallel sequencing studies may lead to a deeper 
understanding of the mutational changes in these genetic backgrounds. 
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Interestingly, other groups described K14Cre-driven models (K14Cre:Brca1f/f:p53f/f 
and K14Cre:Ecadf/f:p53f/f)[32, 33] in which the predominant tumour phenotype was 
not an AME, but rather a more typical luminal-like tumour. We have discussed this 
issue previously[13] but our current results support a model in which the Brca1 and 
Ecad alleles used by Liu and colleagues and Derksen and colleagues are dominant 
over the K14Cre cell-of-origin in driving tumour phenotype in a way in which the 
alleles we have used are not. 
 
Our study has important limitations. While the BlgCre transgene preferentially drives 
tumour formation in lumERneg-cells, we cannot definitively exclude that promoter 
‘leakiness’ may, in a modest number of cases, result in tumours originating from 
other cell types or that initial gene deletions may affect cell differentiation and thus 
alter the phenotype of the cell that finally transforms (see Supplemental Online 
Material); whereas equivalent mouse and human mammary epithelial cell types can 
be inferred (i.e. cells which are luminal or basal, ER-positive or ER-negative), the cell 
types in which allele recombination occurs in the mouse have not been directly 
mapped to human cell types; the mouse strains we have used, while mainly on a 
C57Bl6 background, are not pure bred (see Supplemental Online Material) and there 
may be background strain-specific alleles linked to the conditional alleles which 
could affect tumour phenotypes; in our models, and in all current mouse models 
involving more than one conditional allele, it is not possible to control the order in 
which allele recombination occurs; finally, we have not yet observed tumours that 
resemble sporadic human ER-positive IDC-NSTs with a luminal A molecular profile. 
We hypothesise that either lumERpos-progenitors will need to be targeted as the cell-
of-origin for this tumour type or that these tumours are simply too indolent to be 
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modelled within the mouse lifespan. In general, we note that while mouse models 
are important as models of breast cancer, mice are not humans and caution must be 
exercised in extrapolating results between species, as is illustrated by the case of 
PTEN expression in AMEs. 
 
Despite these limitations, this study does provide a fundamental advance in our 
understanding of the origins of mammary tumour heterogeneity. We provide multiple 
lines of evidence to demonstrate that the phenotype of a cancer is not a mere 
reflection of its cell-of-origin, calling into question conclusions about the histogenesis 
of malignancies derived from histopathological, immunophenotypical and 
transcriptomic analyses of fully developed tumours. 
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PAM50 Correlation to Human Molecular Subtypes 
n (%) 
   
Basal Her2 
Luminal 
A 
Luminal 
B 
Normal 
Breast-like 
Undefined 
Brca1 tumors (n=21) 14 (66.67)* 1 (4.76) 0 (0) 1 (4.76) 5 (23.81) 0 (0) 
 K14Cre 
(n=3) 
2 (66.67) 0 (0) 0 (0) 0 (0) 1 (33.33) 0 (0) 
 BlgCre 
(n=18) 
12 (66.67) 1 (5.56) 0 (0) 1 (5.56) 4 (22.22) 0 (0) 
  Virgin 
(n=12) 
7 (58.33) 1 (8.33) 0 (0) 0 (0) 4 (33.33) 0 (0) 
  Parous 
(n=6) 
5 (83.33) 0 (0) 0 (0) 
1 
(16.67) 
0 (0) 0 (0) 
Brca2 tumors (n=13) 9 (69.23)* 0 (0) 0 (0) 1 (7.69) 2 (15.38) 1 (7.69) 
 K14Cre 
(n=5) 
5 (100) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
 BlgCre 
(n=8) 
4 (50) 0 (0) 0 (0) 1 (12.5) 2 (25) 1 (12.5) 
  Virgin 
(n=4) 
2 (50) 0 (0) 0 (0) 0 (0) 1 (25) 1 (25) 
  Parous 
(n=4) 
2 (50) 0 (0) 0 (0) 1 (25) 1 (25) 0 (0) 
Pten tumors (n=21) 1 (4.76) 0 (0) 3 (14.29) 0 (0) 17 (80.95)** 0 (0) 
 Pten
+/-
 
(n=6) 
0 (0) 0 (0) 0 (0) 0 (0) 6 (100) 0 (0) 
 Pten
f/f
 
(n=15) 
1 (6.67) 0 (0) 3 (20) 0 (0) 11 (73.33) 0 (0) 
    K14Cre 
(n=2) 
1 (50) 0 (0) 0 (0) 0 (0) 1 (50) 0 (0) 
    BlgCre 
(n=13) 
0 (0) 0 (0) 3 (23.08) 0 (0) 10 (76.92) 0 (0) 
  Virgin 
(n=7) 
0 (0) 0 (0) 2 (28.57) 0 (0) 5 (71.43) 0 (0) 
  Parous 
(n=6) 
0 (0) 0 (0) 1 (16.67) 0 (0) 5 (83.33) 0 (0) 
Pten p53 tumors (n=10) 0 (0) 0 (0) 2 (20) 4 (40)*** 3 (30) 1 (10) 
 
p53
f/+
 (n=6) 0 (0) 0 (0) 2 (33.33) 
1 
(16.67) 
2 (33.33) 1 (16.67) 
 p53
f/f
 (n=4) 0 (0) 0 (0) 0 (0) 3 (75) 1 (25) 0 (0) 
 
Table 1. Correlation of tumor molecular profiles to human breast cancer molecular 
phenotypes. Number and percentage of tumors most closely correlating to each category 
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are shown. Undefined indicates samples not classified into any centroid group due to a 
Spearman correlation rank <0.1. Mouse tumors listed by genotype, Cre promoter and 
parity status. Shaded cells indicate the modal correlation. (*) Basal vs non-basal 2 test 
p<0.0001. (**) Normal vs non-normal 2 test p<0.0001. (***) Luminal B vs non-luminal B 2 
test p<0.0001. See Table S4. 
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Figure Legends 
Figure 1. Brca2, Pten, and Pten p53 derived tumours have distinct features. (A) 
Survival curve for K14Cre:Brca2f/f:p53f/f (n=29), virgin (n=21), and parous (n=18) 
BlgCre:Brca2f/f:p53f/f mice. Only data from animals developing mammary tumours 
are shown. K14Cre tumours had a significantly shorter latency (p<0.0001; Log Rank 
Test). (B) Relative abundance of histological phenotypes in Brca2 tumours arising in 
distinct cells of origin. IDC-NST, invasive ductal carcinoma of no special type; AME, 
adenomyoepithelioma; DCIS, ductal carcinoma in situ; MSCT, metaplastic spindle 
cell tumour. (C, D, E, and F) Mitotic index (number of mitotic figures in ten high 
power fields) and percentages of K14-, K18-, and p63-positive cells within Brca2 
tumours. Bars indicate median values. Data points represent individual tumours and 
are coloured according to histological phenotype. (G) Survival curve for Pten+/- 
(n=15), K14cre:Ptenf/f (n=3), virgin (n=43) and parous (n=29) BlgCre:Ptenf/f; and 
Blgcre:Ptenf/f:p53f/+&f/f (n=12) mice. Only data from animals developing malignant 
mammary tumours are shown. (H) Relative abundance of histological phenotypes in 
malignant Pten and Pten p53 tumours. AME, adenomyoepithelioma; Encysted 
Papillary, encysted papillary carcinoma; Adenosquamous, metaplastic 
adenosquamous carcinoma; IDC-NST, invasive ductal carcinoma of no special type; 
MSCT, metaplastic spindle cell tumour. (I, J, K, and L) Mitotic index and distribution 
of K14-, K18-, and p63-positive cells within Pten and Pten:p53 tumours. Bars 
indicate median values. Data points represent individual tumours and are coloured 
according to histological phenotype. Asterisks indicate statistically significant 
differences in t-tests: (*) P<0.05, (**) P<0.01, (***) P<0.001. 
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Figure 2. Brca2 depletion in the mammary epithelium results in a spectrum of 
tumour phenotypes dependent on the cell-of-origin. (A-F) BlgCre:Brca2f/f:p53f/f 
IDC-NST. (A) Low power H&E showing tumour with mixed borders. (B) High power 
H&E showing mitotic figures and nuclear pleomorphism. (C-F) Staining for K14 (C), 
K18 (D), p63 (E) and ER (F). (G-L) BlgCre:Brca2f/f:p53f/f metaplastic spindle cell 
carcinoma. (G) Low power H&E showing tumour with central necrosis. (H) High 
power H&E showing neoplastic epithelioid and spindloid cells. (I, J) K14 (I) and K18 
(J) expression in epithelioid cells but lack of expression in spindle cells. (K) p63 
staining. (L) ER staining. (M-R) K14Cre:Brca2f/f:p53f/f malignant AME. (M, N) Low 
power (M) and high power (N) H&Es showing illustrating the pushing margins of a 
tumour. (O) K14 staining in basal-like neoplastic population. (P) K18 staining in 
luminal-like neoplastic population. (Q) Strong p63 staining in basal-like neoplastic 
cells. (R) Lack of ER staining in neoplastic cells. Bars in (A, G, M) = 1.5 mm. Bars in 
(B-F), (H-L), and (N-R) = 100 μm. Inset boxes are magnified x3. See also Tables S2 
and S3 and Figure S1. 
 
Figure 3. Pten depletion in luminal progenitors generates benign and 
malignant tumours. (A-F) Features of BlgCre:Ptenf/f benign AME. (A, B) Low power 
(A) and high power (B) magnification H&Es. (C) Strong K14 staining in proliferating 
basal cells encasing the glandular structures and in spindle cells. (D) Strong K18 
staining in luminal cells. (E) Strong p63 staining in basal cells. (F) Strong ER staining 
in luminal cells. (G-L) Features of BlgCre:Ptenf/f malignant AME. (G) Low power H&E 
showing multifocal necrosis and pushing borders. (H) High power H&E showing 
gland-like structures and expansion of the abluminally located cells. Note increased 
nuclear pleomorphism. (I) Strong K14 staining in proliferating basal cells and in 
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spindle cells. (J) Strong K18 staining in luminal cells. (K) p63 and (L) ER staining. 
Note the similarity of expression pattern of p63 and ER. (M-R) Features of a 
BlgCre:Ptenf/f tumour showing an adenosquamous carcinoma clone originating from 
an AME. (M) Low power H&E showing multifocal necrosis and mixed borders. (N) 
High power H&E showing metaplastic squamous elements emerging from AME 
area. (O) K14 staining in neoplastic basal-like cells. (P) K18 staining in neoplastic 
luminal cells. (Q) Strong p63 expression in epithelioid cells. (R) ER staining in 
neoplastic epithelioid cells. Bars in (A, G, M) = 1.5 mm. Bars in (B-F), (H-L), and (N-
R) = 100 μm. Inset boxes are magnified x3. See also Tables S2 and S3 and Figures 
S3 and S4.  
 
Figure 4. p53 loss alters tumour phenotypes in Pten knockout mice. (A-F) 
Features of a BlgCre:Ptenf/f:p53f/f IDC-NST. (A) Low power H&E showing central 
necrosis and mixed borders. (B) High-power H&E showing aberrant proliferation of 
highly pleomorphic neoplastic epithelioid cells. (C) K14 staining in neoplastic 
epithelioid cells. (D) K18 staining in neoplastic epithelioid cells. (E) p63 and (F) ER, 
note staining of epithelioid neoplastic cells. (G-L) Features of a BlgCre:Ptenf/f:p53f/+ 
metaplastic spindle cell carcinoma. (G) Low power H&E showing multifocal necrosis 
and mixed borders. (H) High-power H&E showing abundant spindle cells. (I) Lack of 
K14 expression in spindle cells. (J) K18 expression in small nests of epithelioid cells. 
No K18 staining in spindle cells. (K) p63. (L) Tumour cells are negative for ER. (M-R) 
Features of a BlgCre:Ptenf/f:p53f/+ malignant AME. (M) Low power H&E showing 
multifocal necrosis and pushing borders. (N) High-power H&E illustrating 
heterogeneous neoplastic populations. (O) K14 staining in abluminal cells. (P) K18 
expression in pseudo-luminal cells. (Q) Strong p63 expression in proliferating 
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abluminal cells. (R) ER expression in cells located in the abluminal layer. Bars in (A, 
G, M) = 1.5 mm. Bars in (B-F), (H-L), and (N-R) = 100 μm. Inset boxes are magnified 
x3. See also Table S2 and S3 and Figures S5 and S6. 
 
Figure 5. The initiating genetic lesion is the primary determinant of the 
molecular expression pattern of the resulting tumour. (A) Thumbnail image of 
the unsupervised hierarchical clustering of 4,657 Affymetrix probes. (B) Zoomed 
image of the gene expression heatmap showing a selection of significantly 
upregulated genes which define each tumour cluster. (C) Initiating genetic lesion, 
Cre promoter and virgin/parity status information is colour coded. (D) Further 
dendrogram branches can be defined by ER status and histological phenotype. (E) 
Summary of results of SSP analysis using the PAM50 dataset[18] to identify human 
breast cancer subtypes the mouse tumours most closely resemble. White squares 
indicate no association. Expression data of normal mouse populations and Brca1 
tumours was taken from previously published work[13, 34]. Pvclust analysis 
confirmed that the stability of the three main tumour molecular clusters was >90%. 
See Figure S7 and Supplementary Online Material for confirmatory analysis that 
microarray batch variation did not affect clustering. (F) Analysis for enrichment of up- 
and down-regulated gene sets in mouse signatures of Groups 1 (enriched in Brca2 
and Pten:p53 tumors), 2 (enriched in Pten tumors), and 3 (enriched in Brca1 tumors) 
in human breast cancer datasets[3, 22].  Spearman rank correlation values for each 
signature were plotted against dataset molecular phenotypes as correlation 
heatmaps. Note Group 2 and Group 3 signatures correlated with the human luminal 
A / normal breast-like and the basal-like subtypes, respectively (both heatmaps), 
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whereas the Group 1 signature was highly correlated with the human claudin-low 
subtype (right heatmap). See also Figure S8.  
 
Figure 6. Low expression of claudin-related genes in metaplastic spindle cell 
carcinomas. Boxplots showing expression levels for mouse orthologues of human 
genes (Cldn3, Cldn4, Cldn7, and Cdh1) characteristically downregulated in the 
human claudin-low molecular subtype. Mouse tumours were grouped in five 
categories based solely on histological phenotype: MSCT, metaplastic spindle cell 
tumours; IDC-NST, invasive ductal carcinoma of no special type; AME, malignant 
adenomyoepithelioma; ASQC, adenosquamous carcinoma; Benign AME, benign 
adenomyoepithelioma. Note MSCTs overall show lower expression for each of the 
genes as compared with the other phenotypes. These differences are statistically 
significant (one way ANOVA test, p<0.05, indicated by *) for all genes except Cldn4 
(p=0.056). See also Figure S9. 
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Supplementary Online Information 
Supplementary Experimental Procedures 
Origins of mouse lines and breeding strategy 
All animal work was carried out following local ethical review and under the 
authority of UK Home Office Project and Personal Licences. 
 
K14Cre:Brca2f/f:p53f/f mice (mixed FVB/129 Ola background) were obtained 
from Dr Jos Jonkers (Netherlands Cancer Institute, Amsterdam, The 
Netherlands) [1]. Pten+/- mice (FVB background) and Ptenf/f mice (C57Bl6 
background) were obtained from JAX (The Jackson Laboratory, Bar Harbor, 
Maine, USA). BlgCre:Brca1f/f:p53+/- mice (C57Bl6 background) have been 
previously described [2, 3]. 
 
To obtain BlgCre:Brca2f/f:p53f/f mice, the K14Cre:Brca2f/f:p53f/f strain was 
crossed with wild type C57Bl6 mice to generate Brca2f/+:p53f/+ genotypes. 
These were crossed with the BlgCre:Brca1f/f:p53+/- mice to generate BlgCre 
Brca1f/+:Brca2f/+:p53f/+ mice. These were crossed with each other until the 
BlgCre:Brca2f/f:p53f/f genotype was established. 
 
The K14Cre:Ptenf/f strain was obtained by crossing K14Cre:Brca2f/f:p53f/f mice 
with Ptenf/f mice and then mating the offspring until the desired genotype was 
generated. 
 
The BlgCre:Ptenf/f, BlgCre:Ptenf/f:p53f/+ and BlgCre:Ptenf/f:p53f/f strains were 
generated by first crossing BlgCre:Brca1f/f:p53+/- mice with Ptenf/f mice to 
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obtain BlgCre:Brca1f/+:Ptenf/+ and then crossing these animal to obtain 
BlgCre:Ptenf/f. Then, the BlgCre:Ptenf/f mice were crossed with 
BlgCre:Brca2f/f:p53f/f mice to obtain BlgCre:Ptenf/+:Brca2f/+:p53f/+. The 
remaining Brca2 floxed allele was bred out, the Pten floxed allele was bred to 
homogeneity and then the lines maintained by crossing BlgCre:Ptenf/f:p53f/+ 
with BlgCre:Ptenf/f:p53f/f animals. 
 
Therefore, the majority of the mouse tumours, with the exception of the 
K14Cre:Brca2f/f:p53f/f line, have come from a mainly C57Bl6 background, 
although this is still not pure. Furthermore, to generate new combinations of 
alleles we have intercrossed between the strains in order to increase the 
homogeneity of their backgrounds. The distinctly different genetic background 
of the K14Cre:Brca2f/f:p53f/f mice is unlikely to be the reason they developed 
mainly AMEs as this tumour phenotype is seen in other lines in other genetic 
backgrounds, and in particular in the BlgCre:Brca1f/f:p53+/- mouse, which is 
C57Bl6. It is also unlikely that it is genes linked to the p53 floxed allele carried 
over from the K14Cre:Brca2f/f:p53f/f background, rather than the p53 itself, that 
are responsible for the rescue of the MSCT and IDC-NST phenotypes in the 
BlgCre:Ptenf/f:p53f/f animals. This is because IDC-NSTs and MSCTs are seen 
in the BlgCre:Brca1f/f:p53+/- mouse, which is a germline p53 heterozygote 
from a completely different origin [4]. 
 
Cell types targeted in BlgCre models 
A key consideration in the interpretation of these data is the cell of origin of 
the different tumours, particularly in the BlgCre models. Data from our 
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previous studies [3, 5] support a lumERneg origin of BlgCre tumours. In 12 
week old virgin female mice, BlgCre drives recombination in 51% of the total 
lumERneg population and in 77% of cells with in vitro colony forming potential 
(colony forming cells; CFCs) within that population. The ability to form 
colonies in vitro is the standard operational definition of a progenitor cell [6]. In 
contrast, the transgene drives recombination in 0.6% of the total lumERpos 
population and in 1% of CFCs within that population. By 43 weeks of age, the 
numbers are 97% of the CFCs (52% of the total) for the lumERneg population 
and 34% of the CFCs (3% of the total) for the lumERpos population [3]. At 10-
12 weeks of age, the ratio of lumERneg progenitors to lumERpos progenitors 
(as determined by c-Kit expression, which marks luminal progenitors) is 17:1 
[5] and hence the ratio of recombined lumERneg to lumERpos progenitors in the 
resting mammary epithelium is >1000:1 at 12 weeks. Moreover, the overall 
proportion of lumERpos cells declines with age [3]. The most likely cell of origin 
for all BlgCre model tumours, therefore, is lumERneg progenitors. 
 
However, while an origin of ER- tumours in lumERneg progenitors was 
unremarkable, the consistent appearance of ER+ tumours in the 
BlgCre:Pten:p53 models was surprising. The possibility that ER- tumours 
were generated from lumERneg progenitors in BlgCre:Brca1:p53 and 
BlgCre:Brca2:p53 mice and ER+ tumours were generated from lumERpos 
progenitors in BlgCre:Pten:p53 mice must be considered. However, it is highly 
unlikely that recombination of the conditional alleles only occurs in lumERpos 
progenitors in the BlgCre:Pten:p53 mice and in lumERneg progenitors in the 
BlgCre:Brca1/2:p53 mice, as the only difference between these mice is the 
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floxed alleles and any downstream effects of loss of Pten or Brca1/2 must 
happen after switching has occurred, although one cannot definitively exclude 
the possibility that chromatin structure around the Brca1, Brca2 and Pten loci 
is different in these two cell types, altering the likelihood of recombination. If 
one accepts, rather, that BlgCre drives conditional allele recombination 
equally efficiently, on a cell to cell basis, in both lumERneg and lumERpos 
progenitors, and that the ratio of recombined lumERneg to lumERpos 
progenitors is >1000:1, then there must be substantially more lumERneg than 
lumERpos progenitors with deleted conditional alleles in both BlgCre:Pten:p53 
and the BlgCre:Brca1/2:p53 mice. The lumERneg progenitors are, thus, the 
most likely origin of both ER+ and ER- tumours in these models. 
 
A final caveat is that while deletion of Pten and p53 alleles in the 
BlgCre:Pten:p53 mice may be occurring in the same cell type (lumERneg 
progenitors) as deletion of Brca1/2 and p53 alleles in the BlgCre:Brca1/2:p53 
mice, this does not necessarily mean that the cells that actually ‘transform’ 
into a tumour are the same in both cases. Loss of Brca1/2 or Pten alleles in 
the same cell may initially drive that cell along different differentiation 
pathways before the cell actually becomes neoplastic. Thus, it is formally 
possible that loss of Pten could cause ER negative cells to become ER 
positive prior to transformation and thus generate ER positive tumours. 
Without extensive formal lineage tracing analysing the very early stages of 
tumour formation in these models, it is not possible to determine whether or 
not this is occurring. However, the ultimate origin of these tumours, the cell 
type in which recombination occurs, is still the same. The only difference in 
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these scenarios is that in one alternative, recombination is followed by 
transformation and then deleted-allele-specific tumour differentiation, whereas 
in the other recombination is followed by deleted-allele-specific cellular 
differentiation and then transformation. The outcomes of both these scenarios 
are essentially identical. 
 
Cell types targeted in K14Cre models 
The Krt14 gene is most highly expressed in the basal mammary epithelium in 
the adult. However, it is also expressed from early on in development during 
the formation of the embryonic mammary gland. Therefore, the Krt14Cre has 
the potential to be driving recombination at any point from very early to very 
late during mammary development. One might expect, therefore, that the 
Krt14Cre would drive recombination, and thus tumour formation, throughout 
the mammary gland in all animals. However, this is not the case. It has been 
demonstrated that adult mice carrying the allele we have used have 
recombined flox alleles in the majority of basal cells but only in occasional 
luminal cells [1]. This would be consistent with the occasional appearance of 
IDC-NSTs in the K14Cre:Brca1 and K14Cre:Brca2 flox models, but the 
majority of tumours being a different phenotype. Furthermore, the BlgCre and 
Krt14Cre:Brca1 and Brca2 models clearly develop different tumour types. As 
the only difference between these models is the Cre driver (and two different 
KrtCre alleles were used in the Brca1 and Brca2 models) the most likely 
explanation for the different tumour types is different cells of origin. As the 
lineage data supports the lumERneg population as the origin for BlgCre 
tumours, the basal cells must be the origin of the K14Cre tumours. 
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Human material 
This study was performed following standard ethical procedures of the 
Spanish regulation (Ley de Investigación Orgánica Biomédica, 14 July 2007) 
and was approved by the ethics committee of the Hospital Virgen del Rocío 
de Sevilla and the Fundación Pública Andaluza para la Gestión de la 
Investigación en Salud de Sevilla (FISEVI), Spain. Written informed consent 
was obtained and all clinical investigation was been conducted according to 
the principles expressed in the Declaration of Helsinki. 
 
Evaluation of histological phenotypes and immunohistochemistry 
results 
Mouse tumour sections were scored with observers blinded to the genotypes 
of animals on a multiheaded microscope (by LM, MJS and JSR-F). 
Consensus scores were calculated for each marker on each tumour. The final 
histological subtypes were further discussed with two pathologists with an 
interest in breast pathology (DNR and/or FM). Markers were 
semiquantitatively assessed by estimating percentages of morphologically 
unequivocal neoplastic cells displaying either nuclear (ER/p63/PRA/PRB) or 
cytoplasmic (K14/K18) staining. Human tumour samples were assessed by 
MA, MAL-G and JP essentially according to previous criteria [7, 8] and as 
described in the legend to Table S6.  
 
Quantitative Real-Time rtPCR 
Total RNA was isolated from up to 30 mg of frozen tumour material using RLT 
Buffer and RNeasy Mini Kit (Qiagen, Crawley, UK) according to 
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manufacturer’s guidelines. Isolated RNA was subjected to cDNA synthesis 
using QuantiTect Reverse Transcription Kit (Qiagen). qRT-PCR was 
performed using TaqMan Assays-on-Demand probes (Applied Biosystems, 
Paisley, UK; Table S1). Assays were tested on three independent cDNA 
preparations from each tumour. Results were analysed with the Δ-ΔCt method 
normalised to β-Actin and relative to a comparator sample (normal lumERneg 
cells). 
 
Droplet Digital Polymerase Chain Reaction (ddPCR) for floxed/unfloxed 
allele detection 
To measure the tumor depletion of the gene floxed alleles as compared with 
the unfloxed alleles, 50 ng of genomic tumor DNA were also used in a ddPCR 
reaction following manufacturer’s guidelines (ddPCR Supermix for Probes 
#186-3010, Bio-Rad, Hemel Hempstead, Hertforsdhire, UK). Taqman made-
to-order mouse copy number assays for Brca2, Pten, and Trp53, as well as 
Tfrc mouse copy number reference assays were used (Life Technologies, 
Paisley, UK; Table S1). Reactions were performed in duplicates; reference 
(DNA from normal mammary gland cells) and non-template controls were 
added to the study. 
 
Meta-analysis of signatures developed in the mouse in human breast 
cancers 
Based upon SAM pairwise comparison analyses of mouse mammary 
tumours, three different molecular signatures were obtained after applying 
filtering thresholds: Group 1 (120 probes 15-fold up regulated and 91 probes 
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10-fold down regulated in Brca2 and Pten:p53 tumours), Group 2 (92 probes 
10-fold up regulated and 115 probes 10-fold down regulated in Pten tumours), 
and Group 3 (42 probes 5-fold up regulated and 91 probes 5-fold down 
regulated in Brca1:p53 tumours). These gene lists were then matched to each 
external dataset [9-18]. Datasets were annotated for subtype and gene 
symbol. Probes with more than 20% missing values were removed. Missing 
values were imputed using KNN imputation. Replicate probes were removed 
retaining the one with the greatest variance for each gene. 
 
For each dataset, recovered expression values for each gene were tested for 
significant differences across subtypes using a two-tailed ANOVA. Average 
expression values for both up- and down-regulated gene lists across the 
subtypes were bar plotted and pair wise compared using t-test. Additionally, 
for each gene list combining both up and down regulated genes, a Spearman 
rank correlation was performed for each sample. Correlation values were 
reported for each mouse signature and plotted against dataset ordered based 
upon molecular subtype or mutation status as correlation heatmaps. 
 
Assessment of microarray batch variation 
The unexpected clustering of the Brca2:p53 tumours with the Pten:p53 
tumours, rather than the Brca1:p53 tumours may have been an artefact of 
microarray analyses (e.g. batch variation). To test this, we carried out 
quantitative real-time rtPCR analysis of the expression of 22 lineage-
associated genes in all tumour cohorts and in normal mammary epithelial 
subpopulations. We then extracted the gene expression data for the same 22 
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genes from the whole transcriptome arrays. Unsupervised hierarchical 
clustering analyses were performed on both sets of data. The results were in 
strong agreement, this time separating the tumours into two groups (Figure 
S7). One consisted of the Pten cohort together with normal lumERneg and 
lumERpos populations. The other consisted of the Brca1 and Brca2 cohorts 
together with normal basal cell populations. The Pten:p53 tumours were 
scattered amongst the two groups (Figure S7). These results obtained with an 
orthogonal RNA expression analysis method argue against a batch effect in 
the whole transcriptome clustering. 
 
Supplementary Figure and Table Legends 
Figure S1. Expression of Trp53 and Brca2 in Brca2f/f:p53f/f mouse 
tumours. (A-B) Trp53 expression in tumour versus matched (A) or average 
(B) spleens determined with a probe against (floxed) exon 4. (C) Brca2 
expression levels in tumour versus matched spleens determined with probes 
against exon 6 and (floxed) exon 11. Gene expression levels were determined 
by qPCR on triplicate samples from each tumour and are shown as mean 
gene expression levels ±95% confidence limits relative to the comparator 
sample. *No detectable expression. 
 
Figure S2. Copy number analysis for floxed versus unfloxed alleles 
determined by droplet digital-PCR results. (A) Detection of Brca2 alleles in 
Brca2 p53 tumors. (B) Detection of Trp53 alleles in Brca2:p53 tumors. (C) 
Detection of the Trp53 alleles in Pten:p53 tumors. Reference copy number 
value is 2 copies as predicted by gene reference (Tfrc) and further confirmed 
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by normal mammary gland (MG) cells. Error bars indicate the Poisson 95% 
confidence intervals for each copy number determination. X axis crosses Y at 
reference copy number value 2. Note all tumors consistently show lower 
number of copies of the floxed alleles (in asterisks) as compared with the 
unfloxed alleles. Pten analysis could not be performed due to technical 
limitations to assess copy number data in the floxed allele (see 
Supplementary Methods). 
 
Figure S3. Expression of Pten and Trp53 in Ptenf/f and Ptenf/f:p53f/f 
mouse tumours. (A-B) Pten expression levels in tumour versus matched 
spleens determined with probes against (floxed) exon 4 and exon 11 in Ptenf/f 
(A) and Ptenf/f:p53f/f (B) tumours. (C) Trp53 expression in tumour versus 
matched spleens determined with a probe against (floxed) exon 4. Gene 
expression levels were determined by qPCR on triplicate samples from each 
tumour and are shown as mean gene expression levels ±95% confidence 
limits relative to the comparator sample. 
 
Figure S4. Papillary features in benign and malignant AMEs of Pten 
tumours. (A-F) Histological features of a benign BlgCre:Ptenf/f papillary 
adenomyoepithelioma. (A) Low power H&E of benign tumour. (B) High power 
H&E showing tumour cells with palisade-like nuclei tumour cells, typical of 
papillary tumours. (C) K14 staining in basal cells. (D) K18 staining in luminal 
cells. (E) p63 expression in basal cells. (F) ER expression in neoplastic cells 
located in the luminal cells of gland-like structures. (G-L) Histological features 
of a malignant BlgCre:Ptenf/f papillary adenomyoepithelioma. (G) Low power 
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H&E of tumour multifocal necrosis and mixed borders. (H) High power H&E 
showing tumour cells with pleomorphic palisade-like nuclei tumour cells. (I) 
K14 staining in basal cells. (J) K18 staining in luminal cells. (K) p63 
expression in basal cells. (L) Neoplastic cells in both luminal and basal 
regions express ER. Bars in (A, B) = 1.5 mm. Bars in (B-F, H-L) = 100 μm. 
Inset boxes are magnified x3.  
 
Figure S5. Features of benign Pten and Pten:p53 tumours and 
comparison of ER staining in malignant Pten and Pten:p53 tumours. (A-
E) Percentage of tumour cells positive for K14 (A), K18 (B), p63 (C), and ER 
(D) in benign Pten and Pten:p53 tumours. (E) Percentage of tumour cells 
positive for ER in malignant Pten and Pten p53 tumours. (F) Percentage of 
tumour cells positive for PRA in malignant Pten and Pten:p53 tumours. (G – I) 
Staining of a BlgCre:Ptenf/f:p53f/f tumour for ER (G), PRA (H) and PRB (I); 
bars in (G, H, I) = 50 m. Insets are magnified 2.5 x. 
 
Figure S6. Co-localisation of p63 and ER in malignant but not benign 
adenomyoepitheliomas. (A) Dual immunofluorescence staining of benign 
(top, A) and malignant (bottom, B) AME for p63 (green) and ER (red). 
Sections are counterstained with DAPI. Note co-localisation of p63 and ER in 
the malignant tumour (e.g. white arrows) while occasional p63+ ER- nuclei 
(green arrows) and p63- ER+ nuclei (red arrows) demonstrate that the double 
staining was not due to cross reactivity of antibodies. Bar = 70 m. Inset 
panels magnified x3. 
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Figure S7. Affymetric gene expression analysis is not confounded by 
batch variation. Unsupervised hierarchical clustering of gene expression 
data from qPCR analysis of 22 lineage-associated genes (A) and from 
Affymetrix gene expression data (see Figure 5) of the same 22 genes. 
 
Figure S8. Mouse mammary tumor molecular signatures are 
differentially correlated with human breast cancer molecular subtypes. 
(A) Bar plots of the mean expression values for both up- (top) and down-
regulated (bottom) mouse gene lists across the human subtypes in the TCGA 
dataset [10, 15] Error bars indicate the Poisson 95% confidence intervals 
(standard t-test in pairwise comparisons). (B) Spearman rank correlation 
values for each signature plotted against dataset molecular phenotypes from 
additional human breast cancer datasets [13, 14]. (C) As in (A) but tested in a 
dataset in which claudin-low tumours have been annotated [12]. (D) As in (B) 
but again for additional human breast cancer datasets in which claudin-low 
tumours have been annotated [9, 11]. (E) As in (B) but considering human 
familial breast cancers datasets [16-18]. Human samples were BRCA1-
mutated, BRCA2-mutated, non-BRCA1/2 mutated, and sporadic breast 
cancer cases. 
 
Figure S9. Mouse mammary metaplastic spindle cell tumours have 
molecular signatures similar to the human claudin-low breast cancer 
subtype. From low (left) to high expression (right), barplots indicate the 
average expression of genes in the downregulated geneset of the human 
‘claudin-low’ breast cancer subtype [12]. Bars are color coded by genotype 
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and histological phenotypes are indicated below the X-axis.  Note that all 
metaplastic spindle cell tumours in this series (blue boxes) have low 
expression for genes characteristically downregulated in human claudin-low 
tumours. 
 
Figure S10. Immunostaining of human tumours. (A – C) CLDN4 staining of 
(A) a human triple-negative IDC-NST showing strong staining, (B) a human 
triple-negative IDC-NST showing reduced staining and (C) a human 
metaplastic spindle cell tumour showing absence of CLDN4 staining in spindle 
cells. (D – L) Analysis of PTEN expression in human histological subtypes. 
(D) PTEN staining of normal human breast. (E) H&E of benign AME and (F) 
PTEN staining of benign AME. (G) H&E of malignant AME and (H) PTEN 
staining of malignant AME. (I) Triple-negative IDC-NST showing PTEN 
staining. (J) Triple-negative IDC-NST showing absence of PTEN staining in 
tumour cells. (K) PTEN positive metaplastic spindle cell tumour. (L) PTEN 
negative metaplastic spindle cell tumour. Bars A – C = 50 m; bars D – L = 25 
m. 
 
Table S1. (A) Primers used for genotyping. (B) TaqMan gene expression 
assays. 
 
Table S2. Full malignant tumour histological features and 
immunohistochemical findings. Histological type was defined based on the 
World Health Organisation classification [19, 20]; metaplastic carcinomas 
were subtyped according to previously published criteria [21]. Tumours were 
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considered positive for a marker by immunohistochemistry if they contained 
≥1% morphologically unequivocal neoplastic cells with discrete staining 
clearly above background levels. 1Nuclear pleomorphism graded according to 
Elston and Ellis [22]. 2Tubule formation graded according to Elston and Ellis 
[22]. 3Number of mitotic figures in ten high power (x63) fields. 4Borders 
classified as pushing if in >75% of the circumference of the tumour, neoplastic 
cells arranged in sheets and nests compressed without encasing the adjacent 
mammary tissues, as infiltrative if in >75% of the circumference of the tumour, 
neoplastic cells arranged in cords, sheets and nests invaded the adjacent 
mammary tissues encasing normal structures and/or eliciting stromal reaction, 
and as mixed if they contained both elements [23]. 5DCIS was graded based 
on nuclear morphology according to the UK guidelines. 6RNA could be 
extracted from these tumours for qPCR but not either the amount obtained 
was not sufficient for gene expression microarray or the RNA quality failed 
QC. 7Tumours were small and processed for histology only – no frozen 
material was available for molecular analysis. Browse tabs for Brca2, Pten, 
and Pten:p53 tumour data. For Brca1 tumour information, see [3]. 
 
Table S3. Full benign tumour histological features and 
immunohistochemical findings. For details see legend to Table S1. Benign 
tumours were not scored for tumour formation, nuclear pleomorphism or 
mitotic indices. Browse tabs for Pten, and Pten:p53 benign tumour data. 
 
Table S4. Genes upregulated in tumour molecular clusters determined 
by SAM pair-wise comparisons and analysed by Gene Ontology (GO) 
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and KEGG Pathway Analysis. For the SAM analysis, only genes with a fold 
difference in expression of >2 and a P-value and local FDR <0.05 are shown. 
For GO and KEGG analysis, gene lists were uploaded to DAVID [24]. For the 
Group 1 genes, only the most highly expressed 3000 genes were uploaded. 
GO terms associated with a less than 10 genes or a P value > 0.05 were 
excluded from the lists. All KEGG terms are included with no filters. 
 
Table S5. Detailed PAM analysis results. Correlations for each tumour 
comparing tumour molecular profiles human molecular subtypes [11]. 
 
Table S6. Staining of human tumour samples for PTEN, CLDN3, CLDN4 
and CDH1. For claudins and CDH1 sample evaluation, separate 
assessments were performed for the epithelial and mesenchymal components 
in metaplastic carcinomas [25]. For claudins, two parameters were evaluated: 
first, cell membrane staining intensity: 0 (absent), 1 (low), 2 (moderate), and 3 
(high); and second, the percentage of cells with positive staining: 0, 1 (0-1%), 
2 (2-10%), 3 (10-33%), 4 (34-66%), 5 (>66%). The addition of cell membrane 
staining plus percentage of cells with positive staining gave a score from 0 to 
8 which was further categorized. Scores 0, 1 and 2 were considered as 
absent or negligible expression (indicated by a 0 on the table); 3 and 4, as low 
expression (1); 5 and 6, as moderate expression (2); and, lastly, 7 and 8 as 
high expression (3). CDH1 (E-cadherin) was scored as 0, absent; 1, reduced 
expression, less than 50% of cells with positive cell membrane staining; 2, 
conserved expression, when >50% of cells showing strong membrane 
staining. For PTEN, sample evaluation was carried out as described [7] to 
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generate a histoscore. The maximum PTEN histoscore per case is 600. This 
is the result of the addition of the nuclear and cytoplasmic PTEN histoscores. 
IDC-NST-TN, invasive ductal carcinoma of no special type but with triple 
negative phenotype; MC_M, mesenchymal-type metapastic cercinoma 
carcinoma, which can have chondrosarcomatous differentiation 
(MC_M_CHR), or osteosarcomatous differentiation (MC_M_OST); MC_SC, 
spindle cell-type  metaplastic carcinoma equivalent to mouse MSCT; AME, 
adenomyoepithelioma; NA, not analyzed because component was not 
observed or no immunostaining performed. 
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